Knobbe Martens Olson & Bear

Practice Areas | News | Patent | Vault Profile | NALP

Rating are based on thousands of associate surveys.

URL: www.kmob.com
Main Office: Irvine
Participating Offices: N/A
Prestige [?]: N/A
Compensation [?]: N/A
Hours worked [?]: N/A
 
Place to stay [?]: N/A
Lifestyle [?]: N/A
Progression potential [?]: N/A
 
Diversity commitment [?]: N/A
Pro Bono dedication [?]: N/A
User rating [?]:
N/A

Write a comment about this firm and share your views.

Most useful comments (See all comments)

No comments have yet been rated as useful.


Most recent comments (See all comments)

There are no comments.

Ratings principally based on over 6,500 associate surveys (3rd-5th years). See The American Lawyer's 2006 Midlevel Associates Survey.

Firm News

FDA Approves Bayer's myBETAapp™JD Supra (press release)On May 30, 2017, Bayer announced FDA approval of a supplemental Biologics License Application for Bayer's myBETAapp™ and BETACONNECT Navigator™. The myBETAapp joins the growing field of medical mobile applications, which the FDA predicts ...and more »
Supreme Court Will Decide Whether IPRs Are UnconstitutionalJD Supra (press release)The Supreme Court granted a petition for writ of certiorari to address whether inter partes review – an adversarial process used by the Patent Office to determine the validity of existing patents – is unconstitutional in Oil States Energy Services, LLC …and more »
FDA to Create New Digital Health UnitJD Supra (press release)The FDA has announced that it will create a new unit responsible for overseeing digital health products. According to Bakul Patel, the Associate Center Director for Digital Health at FDA, the agency is working to define “what clinical validation looks …
FDA Approves Final Label for Syndros™JD Supra (press release)On May 24, 2017, the Food and Drug Administration (FDA) approved the final label for Syndros™ (dronabinol) oral solution, a Schedule II (CII) controlled substance. Syndros™ was initially approved by the FDA on July 5, 2016 for use in treating …
Medtronic's Recent Interactions with the FDAJD Supra (press release)It has been a busy couple of months between Medtronic and the Food and Drug Administration (FDA), with Medtronic experiencing both recalls and approvals from the government agency. Below is a brief summary of some recent of Medtronic's recent ...
Shoe Maker Buscemi Sues J/Slides for Design Patent InfringementJD Supra (press release)Buscemi, LLC (“Buscemi”) filed for a design patent on June 2, 2016. In March 2017, while the patent application was pending, Buscemi alleges that it became aware that Styleline Studios International and JSL Studio International d/b/a J/Slides …and more »
Philips Buys RespirTech for Undisclosed AmountJD Supra (press release)Dutch conglomerate Philips recently announced that it will purchase Respiratory Technologies Inc. (RespirTech). According to its website, RespirTech describes itself as a St. Paul, Minnesota-based provider of inCourage vests, which help fight …and more »
JD Supra (press release)
FDA Approves “First-of-its-kind” Infant Medical DeviceJD Supra (press release)The U.S. Food and Drug Administration (FDA) recently authorized the use of what it described as a “first-of-its-kind” medical device to treat infants for a birth defect called esophageal atresia, in which the upper esophagus is disconnected from the …and more »
Boston Scientific closes acquisition of TAVI device company, SymetisJD Supra (press release)On March 30, 2017, Boston Scientific announced an agreement to acquire Symetis SA, a privately-held Swiss company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in cash. The acquisition expands ...
The Top Hits: Fashion Cases with a Big ImpactJD Supra (press release)Over the last year, there have been some significant trademark and copyright cases in the fashion industry. Below are summaries of recent cases all brand owners should know and understand. These cases touch on important topics in trademark and ...
Valid XHTML 1.0 Transitional
Valid CSS!
Google+